$734.39
0.76% yesterday
Nasdaq, Sep 23, 10:00 pm CET
ISIN
US04016X1019
Symbol
ARGX

argenx SE ADR Stock price

$734.39
+57.07 8.43% 1M
+126.44 20.80% 6M
+119.39 19.41% YTD
+205.89 38.96% 1Y
+391.19 113.98% 3Y
+488.54 198.71% 5Y
+711.39 3,093.00% 10Y
+711.39 3,093.00% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-5.64 0.76%
ISIN
US04016X1019
Symbol
ARGX
Industry

Key metrics

Basic
Market capitalization
$45.6b
Enterprise Value
$41.8b
Net debt
positive
Cash
$3.9b
Shares outstanding
61.2m
Valuation (TTM | estimate)
P/E
37.7 | 49.7
P/S
15.0 | 11.3
EV/Sales
13.7 | 10.3
EV/FCF
135.3
P/B
7.5
Financial Health
Equity Ratio
88.7%
Return on Equity
15.2%
ROCE
7.6%
ROIC
33.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.1b | $4.0b
EBITDA
$488.8m | $808.8m
EBIT
$466.6m | $992.5m
Net Income
$1.3b | $903.7m
Free Cash Flow
$308.7m
Growth (TTM | estimate)
Revenue
- | 84.8%
EBITDA
- | 17,455.2%
EBIT
- | 7,184.2%
Net Income
- | 8.5%
Free Cash Flow
194.9%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
16.0% | 20.0%
EBIT
15.3%
Net
42.0% | 22.3%
Free Cash Flow
10.1%
More
EPS
$19.5
FCF per Share
$5.0
Short interest
3.3%
Employees
2k
Rev per Employee
$1.4m
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a argenx SE ADR forecast:

24x Buy
96%
1x Hold
4%

Analyst Opinions

25 Analysts have issued a argenx SE ADR forecast:

Buy
96%
Hold
4%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,051 3,051
-
100%
- Direct Costs 323 323
-
11%
2,728 2,728
-
89%
- Selling and Administrative Expenses 1,165 1,165
-
38%
- Research and Development Expense 1,170 1,170
-
38%
489 489
-
16%
- Depreciation and Amortization 22 22
91% 91%
1%
EBIT (Operating Income) EBIT 467 467
-
15%
Net Profit 1,280 1,280
-
42%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Neutral
Business Wire
6 days ago
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx' drug s...
Neutral
Seeking Alpha
7 days ago
argenx SE - Special Call Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Roeland Vanhauwaert Peter Ulrichts - Chief Scientific Officer Luc Truyen - Chief Medical Officer Rebecca Shilling Jeff Guptill Tim Van Hauwermeiren - Co-Founder, CEO & Executive Director Conference Call Participants Steven Burden Ricardo Maselli Danielle Brill Bonge...
Positive
Seeking Alpha
12 days ago
argenx's blockbuster Vyvgart drives rapid growth, but heavy reliance on one product and US sales creates concentration risk. The company's robust R&D investment and Immunology Innovation Program fuel a strong pipeline, with empasiprubart showing promising diversification potential. Risks include intense competition, potential loss of exclusivity, and US pricing policy changes, but argenx's larg...
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argenx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today